Octopamine

OTHER NAME(S): 1-(p-Hydroxyphenyl)-2-aminoethanol, 4-(2-Amino-1-hydroxyethyl)phenol, Alpha-(Aminoethyl)-4-hydroxybenzenemethanol, Alpha-(Aminoethyl)-p-hydroxybenzyl alcohol, Alpha-Aminoethyl-4-hydroxybenzylalkohol, Analet, Benzenemethanol, Alpha-(aminomethyl)-4-hydroxy-, Beta-Hydroxytyramine, Demethylsynephrine, Demethylated Synephrine, Norden, Norfen, Norphen, Norsympathol, Norsympatol, Norsynephrine, Octapamine, Octopamine Hydrochloride, Octopaminum, P-Hydroxyphenylethanolamine, P-Norsynephrin, P-Octopamine, Para-Hydroxyphenylethanolamine, Para-Octopamine, Paraoxyphenyl Aminoethanol, WV 562-Isooctyl amine, Octopamina

Overview

Octopamine is a chemical that is found in bitter orange and other plants, and in the human body in small amounts. It is also made in the lab. Octopamine is banned by the World Anti-Doping Agency (WADA) for use during competitive sports. Octopamine is found in some dietary supplements. However, the US Food and Drug Administration (FDA) cautions against its use and is investigating whether octopamine should be allowed in dietary supplements.

Octopamine is commonly used for weight loss and athletic performance, but there is no good scientific evidence to support these uses.

Octopamine is a chemical in the body that helps the brain and nervous system function normally. There isn't enough reliable information to know how octopamine supplements might work.

Octopamine is a chemical in the body that helps the brain and nervous system function normally. There isn't enough reliable information to know how octopamine supplements might work.

References
  1. Penzak SR, Jann MW, Cold JA, et al. Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmacol 2001;41:1059-63.
  2. Visentin V, Morin N, Fontana E, et al. Dual action of octopamine on glucose transport into adipocytes: inhibition via beta3-adrenoceptor activation and stimulation via oxidation by amine oxidases. J Pharmacol Exp Ther 2001;299:96-104.
  3. D'Andrea G, Terrazzino S, Leon A, et al. Elevated levels of circulating trace amines in primary headaches. Neurology 2004;62:1701-5.
  4. Health Canada. Synephrine, Octopamine and Caffeine Health Risk Assessment (HRA) Report. Approved May 16, 2011. Accessed November 6, 2019. Available at: https://www.nutratechinc.com/advz/Studies2011/Safety/S1%20Health%20Canada%200511.pdf.
  5. Pawar RS, Grundel E. Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs). Drug Test Anal 2017;9:500-517.
  6. Mercader J, Wanecq E, Chen J, Carpéné C. Isopropylnorsynephrine is a stronger lipolytic agent in human adipocytes than synephrine and other amines present in Citrus aurantium. J Physiol Biochem. 2011;67(3):443-52.
  7. Zhao J, Wang M, Avula B, Khan IA. Detection and quantification of phenethylamines in sports dietary supplements by NMR approach. J Pharm Biomed Anal. 2018;151:347-355.
  8. Beaumont RE, Cordery P, James LJ, Watson P. Supplementation with a low-dose of octopamine does not influence endurance cycling performance in recreationally active men. J Sci Med Sport. 2017;20(10):952-956.
  9. D'Andrea G, Nordera G, Pizzolato G, et al. Trace amine metabolism in Parkinson's disease: low circulating levels of octopamine in early disease stages. Neurosci Lett. 2010;469(3):348-51.
  10. Smedema JP, Müller GJ. Coronary spasm and thrombosis in a bodybuilder using a nutritional supplement containing synephrine, octopamine, tyramine and caffeine. S Afr Med J. 2008;98(5):372-3.
  11. Bunzow JR, Sonders MS, Arttamangkul S, et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001;60(6):1181-8.
  12. Carpéné C, Galitzky J, Fontana E, Atgié C, Lafontan M, Berlan M. Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn Schmiedebergs Arch Pharmacol. 1999;359(4):310-21.
  13. Thevis M, Koch A, Sigmund G, Thomas A, Schänzer W. Analysis of octopamine in human doping control samples. Biomed Chromatogr. 2012;26(5):610-5.
  14. D'Andrea G, Granella F, Leone M, Perini F, Farruggio A, Bussone G. Abnormal platelet trace amine profiles in migraine with and without aura. Cephalalgia. 2006;26(8):968-72.
  15. Fontana E, Morin N, Prévot D, Carpéné C. Effects of octopamine on lipolysis, glucose transport and amine oxidation in mammalian fat cells. Comp Biochem Physiol C Toxicol Pharmacol. 2000;125(1):33-44.
  16. David JC, Coulon JF, Delacour J. Behavioural and neurochemical effects of intracerebroventricular administrations of p-octopamine in rats. Brain Res. 1982 10;241(2):299-306.
  17. Nespoli A, Bevilacqua G, Staudacher C, Rossi N, Salerno F, Castelli MR. Pathogenesis of hepatic encephalopathy and hyperdynamic syndrome in cirrhosis. Role of false neurotransmitters. Arch Surg. 1981;116(9):1129-38.
  18. Bucci L, Chiaverelli R. Hepatic encephalopathy EEG and octopamine. J Clin Psychiatry. 1980;41(5):175-7.
  19. U.S. Food & Drug Administration. Dietary supplement ingredient advisory list. https://www.fda.gov/food/dietary-supplement-products-ingredients/dietary-supplement-ingredient-advisory-list. Accessed September 19, 2019.